Physician profile
Michelle Jimenez
NPI 1689371478
$4,510.42
in general payments reported to CMS, 2019-2025
30 companies · $1,484 in 2025
The $1,484 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $644 · 2024: $2,382 · 2025: $1,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,510.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $404.51 | 2025 | Yorvipath, Skytrofa |
| Gilead Sciences, INC. | $350.65 | 2024-2025 | Livdelzi, Vemlidy |
| Alexion Pharmaceuticals, INC. | $313.75 | 2023-2024 | Koselugo |
| Amgen INC. | $265.75 | 2024-2025 | Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $249.89 | 2024-2025 | |
| Kyowa Kirin, INC. | $243.80 | 2024 | |
| Xeris Pharmaceuticals, INC. | $229.27 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Abbott Laboratories | $199.00 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Sanofi-Aventis U.S. LLC | $163.66 | 2024-2025 | |
| Abiomed | $125.69 | 2025 | |
| Abbvie INC. | $124.98 | 2024 | |
| Phathom Pharmaceuticals, INC. | $123.15 | 2024 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $122.07 | 2024 | Rexulti |
| Genzyme Corporation | $121.52 | 2024 | |
| Novo Nordisk INC | $121.52 | 2024 | Novoseven |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $120.46 | 2024 | Andexxa |
| Inspire Medical Systems, INC. | $118.62 | 2023 | Inspire |
| Molnlycke Health Care US, LLC | $117.98 | 2024-2025 | Hibiclens, Hubs, Tortoise Turning & Positioning System |
| Acadia Pharmaceuticals INC | $117.54 | 2025 | Nuplazid |
| Sobi, INC | $116.70 | 2024 | |
| Jazz Pharmaceuticals INC. | $115.50 | 2024 | |
| Alk-Abello, INC | $98.99 | 2024 | |
| Pharming Healthcare, INC. | $97.29 | 2023 | Joenja |
| Regeneron Healthcare Solutions, INC. | $97.08 | 2025 | Dupixent |
| Vertex Pharmaceuticals Incorporated | $96.19 | 2025 | |
| Biogen, INC. | $68.61 | 2023 | |
| Eisai INC. | $63.73 | 2025 | |
| Lundbeck LLC | $60.21 | 2025 | Rexulti |
| Medtronic, INC. | $37.83 | 2023 | Intellis Adaptivestim |
| Coloplast Corp | $24.48 | 2023 | Altis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.